Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy with Dual Targeting of CD19 and CD70 to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Sanfang Tu, Lijuan Zhou, Rui Huang, Xuan Zhou, Jilong Yang, Meifang Li, Bo Jin, Langqi Wang, Yaqi Zhuo, Huifang Chen, Lung-Ji Chang, Yuhua Li

Blood (2023) 142 (Supplement 1): 3492.

https://doi.org/10.1182/blood-2023-186888

Published: 2023

Journal Articles

Dendritic Cell Vaccines Extend CD19 CAR-T Cell Persistence and Improve the Outcomes in Refractory/Relapsed Adult B-ALL

Sanfang Tu, Lijuan Zhou, Rui Huang, Yanjie He, Xuan Zhou, Jilong Yang, Yuxing Hu, Honghao Zhang, Lung-Ji Chang, Yuhua Li

Blood (2023) 142 (Supplement 1): 3488.

https://doi.org/10.1182/blood-2023-186308

Published: 2023

Journal Articles

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Combined with Zanubrutinib in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Langqi Wang, Jilong Yang, Bo Jin, Bo Wang, Lijuan Zhou, Yaqi Zhuo, Huifang Chen, Lung-Ji Chang, Sanfang Tu, Yuhua Li

Blood (2023) 142 (Supplement 1): 4841.

https://doi.org/10.1182/blood-2023-186439

Published: 2023

Journal Articles

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD22 to Treat Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults

Sanfang Tu, Lijuan Zhou, Rui Huang, Xuan Zhou, Jilong Yang, Meifang Li, Bo Jin, Langqi Wang, Yaqi Zhuo, Huifang Chen, Lung-Ji Chang, Yuhua Li

Blood (2023) 142 (Supplement 1): 6884.

https://doi.org/10.1182/blood-2023-186622

Published: 2023

Journal Articles

CAR-T Therapy for a Child with Refractory Inflammatory Myofibroblastic Tumor

Kai Wang, Yan Liu, Lung-Ji Chang, Huyong Zheng

Blood (2022) 140 (Supplement 1): 10355–10356.

https://doi.org/10.1182/blood-2022-165248

Published: 2022

Journal Articles

Sequential GD2 Chimeric Antigen Receptor T Cell Therapy (4SCAR2.0-GD2) for the Treatment of Refractory/Relapsed Neuroblastoma

Yuchen Liu, Jingfu Wang, Suyi Kang, Rui Zhang, Lung-Ji Chang

Blood (2022) 140 (Supplement 1): 7462–7463.

https://doi.org/10.1182/blood-2022-164461

Published: 2022

Journal Articles

Pro-Active 4SCAR2.0 Therapy with NGS-MRD Disease Monitoring in High-Risk B Cell Leukemia Management

Cheng Jiao, Yuchen Liu, Rui Zhang, Weihong Chen, Lung-Ji Chang

Blood (2022) 140 (Supplement 1): 12744–12745.

https://doi.org/10.1182/blood-2022-159884

Published: 2022

Journal Articles

Improved Lentiviral In Vivo Gene Therapy for Chronic Granulomatous Disease

Haokun Yuan, Hongwei Liu, Xiaomei Wu, Yuchen Liu, Rui Zhang, Lung-Ji Chang

Blood (2022) 140 (Supplement 1): 4921–4922.

https://doi.org/10.1182/blood-2022-159862

Published: 2022

Journal Articles

Intravenous Lentiviral Gene Therapy for Hemophilia a: Endothelial-Specific Expression and Increased Glycosylation for Improved FVIII Function

Jie Gong, Yuchen Liu, Min Zhou, Lung-Ji Chang

Blood (2022) 140 (Supplement 1): 10650–10651.

https://doi.org/10.1182/blood-2022-159840

Published: 2022

Journal Articles

Intravenous Lentiviral Gene Therapy for Hemophilia a: In Vitro and In Vivo Assessment of Universal Versus Tissue-Specific Promoters

Jie Gong, Tsai-Hua Chung, Min Zhou, Lung-Ji Chang

Blood (2021) 138 (Supplement 1): 2941.

https://doi.org/10.1182/blood-2021-147686

Published: 2021

Journal Articles

Improved Safety and Efficacy of a Multi-Target Chimeric Antigen Receptor Modified T Cell Therapy (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Rui Zhang, MSc, Yuhua Li, MD& PhD, Sanfang Tu, MD& PhD, Rui Huang, MD& PhD, Xun Lai, MD, Leping Zhang, MD PhD, Eugene E. Zvonkov, MD PhD, Valeriy G. Savchenko, MD PhD, Nelly G Gabeeva, PhD, Yuchen Liu, MSc, Yuchen Li, MSc, Cheng Jiao, MD PhD, Lan Deng, MD PhD, Xuan Zhou, MD, Hongyu Zhang, MD PhD, Wenli Zhang, MD, Lung-Ji Chang, PhD

Blood (2020) 136 (Supplement 1): 47.

https://doi.org/10.1182/blood-2020-141515

Published: 2020

Journal Articles

CAR2.0 Therapy for the Management of Post-Transplantation Relapse of B-Cell Acute Lymphoblastic Leukemia

Blood (2020) 136 (Supplement 1): 7.

https://doi.org/10.1182/blood-2020-141531

Published: 2020

Journal Articles

A Novel Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD123 to Treat Relapsed Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Sanfang Tu, MD PhD, Lan Deng, MD PhD, Rui Huang, MD PhD, Xuan Zhou, MD, Jilong Yang, MD, Weijun Zhou, MD PhD, Meifang Li, MD PhD, Chunyan Yue, MD, Shaojie Wu, MD PhD, Zhenling Guo, Lung-Ji Chang, PhD, Yuhua Li, MD PhD

Blood (2018) 132 (Supplement 1): 4015.

https://doi.org/10.1182/blood-2018-99-118526

Published: 2018

Journal Articles

Therapy of 4s Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival with No Severe CRS or Cres in Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia

Sanfang Tu, MD PhD, Rui Huang, MD PhD, Lan Deng, MD PhD, Xuan Zhou, MD, Yanjie He, MD PhD, Weijun Zhou, MD PhD, Jilong Yang, MD, Chunyan Yue, MD, Anqin Wu, Meifang Li, MD PhD, Zhenling Guo, Lung-Ji Chang, PhD, Yuhua Li, MD PhD

Blood (2018) 132 (Supplement 1): 2696.

https://doi.org/10.1182/blood-2018-99-118928

Published: 2018

Journal Articles

Combination of CD19 and CD70 Specific Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival in Relapsed and Refractory Primary Central Nervous System Diffuse Large B Cell Lymphoma

Sanfang Tu, MD PhD, Rui Huang, MD PhD, Xuan Zhou, MD, Yanjie He, MD PhD, Zhao Liang, MD PhD, Lei Wang, MD PhD, Lung-Ji Chang, PhD, Yuhua Li, MD PhD

Blood (2018) 132 (Supplement 1): 5389.

https://doi.org/10.1182/blood-2018-99-117694

Published: 2018

Journal Articles

Phase I/II Trial of Multi-Target Chimeric Antigen Receptor Modified T Cells (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Lung-Ji Chang, PhD, Yuhua Li, MD& PhD, Sanfang Tu, MD& PhD, Xun Lai, MD, Rui Huang, MD& PhD, Shih-Ting Tsao, MSc, Yu-Chen Liu, MSc, Rui Zhang, MSc, Lan Deng, MDPhD, Xuan Zhou, MD, Hongyu Zhang, PhD MD, Wenli Zhang, MD, Yuchen Li, MSc

Blood (2018) 132 (Supplement 1): 225.

https://doi.org/10.1182/blood-2018-99-114396

Published: 2018

Journal Articles

Double CD19/CD22 Chimeric Antigen Receptor-Modified T Cells for the Treatment of Stage IV Relapsed and Refractory Follicular Lymphoma

Xun Lai, MD, Xuezhong Gu, MD, Shih-Ting Tsao, MSc, Qin Zhang, PhD, Yu-Chen Liu, MSc, Jiang Yaxian, PhD, Li Yan, MD, Jun Chun, MD, Rui Zhang, MSc, Yunyun Du, MD, Xiaoli Gao, MD, Yingyu Yang, Xiaolian Qiu, Mingjing Fang, MA, Song Wei, PhD, Lung-Ji Chang, PhD

Blood (2017) 130 (Supplement 1): 5154.

https://doi.org/10.1182/blood.V130.Suppl_1.5154.5154

Published: 2017

Journal Articles

Durable Remission after Salvage Chemotherapy with Combining Bortezomib and Vorinostat Followed By CD19 CAR-T Therapy in a Patient with MLL-Rearranged ALL after Early Relapse Post Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2017) 130 (Supplement 1): 3334.

https://doi.org/10.1182/blood.V130.Suppl_1.3334.3334

Published: 2017

Journal Articles

Chimeric Antigen Receptor 4SCAR-GD2-Modified T Cells Targeting High-Risk and Recurrent Neuroblastoma: A Phase II Multi-Center Trial in China

Lihua Yang, MDPhD, Xiaoli Ma, MDPhD, Yu-Chen Liu, MSc, Wen Zhao, MDPhD, Lihua Yu, PhD, Maoquan Qin, MDPhD, Guanghua Zhu, MDPhD, Kai Wang, MDPhD, Xiaodong Shi, MD, Zhaoxia Zhang, MD, Jingfu Wang, MD, Yuan Sun, MD, Lujia Dong, MD, Shih-Ting Tsao, MSc, Rui Zhang, MSc, Lung-Ji Chang, PhD

Blood (2017) 130 (Supplement 1): 3335.

https://doi.org/10.1182/blood.V130.Suppl_1.3335.3335

Published: 2017

Journal Articles

CD19 Epitope Escape after 4SCAR19 T Cell Therapy Resulted in Re-Establishment of Chemo-Sensitivity in Adult B-Cell Acute Lymphocytic Leukemia Patients

Xun Lai, MD, Jian-Qiong Liu, MD, Lujia Dong, MD, Hong-Mei Ou-Yang, PhD, Zi-Jin Dian, PhD, Jian-Xin Song, PhD, Ya-Xian Jiang, PhD, Xiang-Mei Yao, MD, Xue-Zhong Gu, MD, Xiao-Li Gao, MD, Ya-Yun Wu, MD, Lung-Ji Chang, PhD

Blood (2016) 128 (22): 1633.

https://doi.org/10.1182/blood.V128.22.1633.1633

Published: 2016

NARROW

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy with Dual Targeting of CD19 and CD70 to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Dendritic Cell Vaccines Extend CD19 CAR-T Cell Persistence and Improve the Outcomes in Refractory/Relapsed Adult B-ALL

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Combined with Zanubrutinib in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD22 to Treat Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults

CAR-T Therapy for a Child with Refractory Inflammatory Myofibroblastic Tumor

Sequential GD2 Chimeric Antigen Receptor T Cell Therapy (4SCAR2.0-GD2) for the Treatment of Refractory/Relapsed Neuroblastoma

Pro-Active 4SCAR2.0 Therapy with NGS-MRD Disease Monitoring in High-Risk B Cell Leukemia Management

Improved Lentiviral In Vivo Gene Therapy for Chronic Granulomatous Disease

Intravenous Lentiviral Gene Therapy for Hemophilia a: Endothelial-Specific Expression and Increased Glycosylation for Improved FVIII Function

Intravenous Lentiviral Gene Therapy for Hemophilia a: In Vitro and In Vivo Assessment of Universal Versus Tissue-Specific Promoters

Improved Safety and Efficacy of a Multi-Target Chimeric Antigen Receptor Modified T Cell Therapy (4SCAR2.0) Against Relapsed or Refractory Lymphomas

CAR2.0 Therapy for the Management of Post-Transplantation Relapse of B-Cell Acute Lymphoblastic Leukemia

A Novel Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD123 to Treat Relapsed Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Therapy of 4s Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival with No Severe CRS or Cres in Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia

Combination of CD19 and CD70 Specific Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival in Relapsed and Refractory Primary Central Nervous System Diffuse Large B Cell Lymphoma

Phase I/II Trial of Multi-Target Chimeric Antigen Receptor Modified T Cells (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Double CD19/CD22 Chimeric Antigen Receptor-Modified T Cells for the Treatment of Stage IV Relapsed and Refractory Follicular Lymphoma

Durable Remission after Salvage Chemotherapy with Combining Bortezomib and Vorinostat Followed By CD19 CAR-T Therapy in a Patient with MLL-Rearranged ALL after Early Relapse Post Allogeneic Hematopoietic Stem Cell Transplantation

Chimeric Antigen Receptor 4SCAR-GD2-Modified T Cells Targeting High-Risk and Recurrent Neuroblastoma: A Phase II Multi-Center Trial in China

CD19 Epitope Escape after 4SCAR19 T Cell Therapy Resulted in Re-Establishment of Chemo-Sensitivity in Adult B-Cell Acute Lymphocytic Leukemia Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only